334 / 1708
Group 4 Medulloblastoma
•
Intermediate to good prognosis similar to patients
with SHH tumours
•
Include classical and large cell/anaplastic
histologies
•
Approx 30–40% of MB cases
•
M:F ratio 3:1
•
Molecular pathogenesis not currently clear